ALS Society

of Manitoba


La Société

Manitobaine de la SLA


Pharmacare to Cover Albrioza

Posted on August 31, 2023 by Matthew Honey

The ALS Society of Manitoba and Amylyx Pharmaceuticals Canada are thrilled to announce Pharmacare to cover ALBRIOZA. It has been added to the Manitoba Pharmacare drug benefit program effective August 24, 2023.

Provincial Pharmacare to Cover Albrioza

ALBRIOZA is used for the treatment of amyotrophic lateral sclerosis (ALS) and offers those living with ALS the possibility of extending their period of functional independence, granting them invaluable additional time.

“We commend the Government of Manitoba for it’s decision to offer public coverage for this treatment,” said Diana Rasmussen. “As this fatal disease progresses so quickly, access to approved treatment options represents a lifeline of hope and dignity for those battling this devastating disease.”

Learn More About ALS

Provincial Pharmacare to Cover Albrioza